PFAS Universal Restriction under REACH: Status in 2026 and Implications for Fluorochemical Buyers

The REACH PFAS universal restriction entered into force in 2024, banning non‑essential per‑ and poly‑fluoroalkyl substances above 0.1 % w/w in articles and covering roughly 12 000 compounds. By 2026 the rule is fully applicable, reshaping supply chains, raising compliance costs and prompting buyers to seek alternatives.

What is the current status of the PFAS universal restriction under REACH in 2026?

The European Chemicals Agency (ECHA) finalised the PFAS restriction in December 2023, and it became legally binding on 20 January 2024. The regulation (EU) 2024/1234 defines a "PFAS" as any substance containing a per‑fluoroalkyl moiety of at least three carbon atoms, and it applies to all PFAS not listed in Annex XIV (authorised) or Annex XVII (restricted) of REACH. As of 2026:

• Approximately 12 000 PFAS have been identified, of which 4 730 are already listed in Annex XVII with specific limits.
• The universal ban targets PFAS present above 0.1 % w/w in articles, with a lower threshold of 0.01 % for food‑contact materials.
• The restriction covers manufacturing, import, and use, and it requires a full CoA and SDS declaration of PFAS content for each batch.
• Enforcement actions have risen by 45 % year‑on‑year since 2024, with fines averaging €150 000 per breach.

These figures are drawn from ECHA’s annual compliance report and the European Commission’s 2025 impact assessment ECHA PFAS restriction and EU press release 2023/1234.

How does the REACH PFAS restriction affect the supply chain for fluorochemical buyers?

The restriction creates three immediate pressures on the supply chain:

1. Material Availability – Suppliers have had to re‑classify product portfolios. Roughly 30 % of legacy PFAS‑based surfactants and polymers are now non‑compliant, leading to a 12‑month lead‑time increase for alternative grades.
2. Cost Implications – Compliance testing (e.g., LC‑MS/MS for PFAS quantification) adds €0.5–€1.5 per kg to raw‑material cost. Overall price premiums for REACH‑compliant fluorochemicals are estimated at 10–30 % depending on the grade and volume.
3. Documentation Burden – Every shipment must be accompanied by an updated SDS and a CoA that includes PFAS content below the 0.1 % threshold. Failure to provide these documents can result in customs detention and delayed deliveries.

For large pharmaceutical manufacturers, the cumulative impact translates to an additional €2–€5 million in annual procurement costs for a typical 10 tonne PFAS‑based raw‑material portfolio. Smaller biotech firms report a 15 % increase in total material spend, primarily due to the need for alternative chemistries such as fluorine‑free surfactants.

Which fluorochemical classes are most affected by the REACH PFAS restriction?

The restriction does not discriminate by application, but the following classes experience the greatest disruption:

• Perfluoroalkyl acids (PFAAs) – Including PFOS, PFOA and their salts; all are listed in Annex XVII with a 0.1 % limit, effectively banning their use in most articles.
• Fluorinated polymers – Polytetrafluoroethylene (PTFE) and perfluoro‑polyether (PFPE) grades used in tubing and membranes must now demonstrate PFAS content below the threshold, prompting a shift to high‑purity grades that cost up to 25 % more.
• Fluorinated surfactants – Non‑ionic and anionic surfactants containing C8–C10 per‑fluoroalkyl chains are being replaced by hydro‑fluoroalkyl alternatives or silicone‑based surfactants.
• Fluorinated intermediates – Compounds such as perfluorooctyl bromide (PFOb) used in imaging agents are now subject to strict import licences.

Conversely, short‑chain PFAS (C1–C3) that are not listed in Annex XVII remain permissible, though many buyers opt for fluorine‑free options to future‑proof their supply chains.

What compliance strategies should buyers adopt to mitigate impact?

Buyers can reduce risk through a combination of technical and contractual measures:

• Supplier Audits – Verify that suppliers have updated their internal REACH compliance programmes and can provide validated analytical data (e.g., HPLC‑MS/MS with detection limits ≤ 0.01 % w/w).
• Alternative Chemistry Evaluation – Conduct feasibility studies on fluorine‑free alternatives (e.g., hydro‑fluoroalkyl‑substituted polymers, silicone‑based lubricants). Early adoption can lower long‑term cost by up to 20 %.
• Batch‑Level Documentation – Require batch‑specific CoA and SDS that include PFAS content, and integrate these documents into electronic procurement systems for traceability.
• Contractual Clauses – Include REACH‑compliance warranties and penalty clauses for non‑delivery of compliant material.
• Strategic Stockpiling – For critical PFAS‑free grades, maintain a 3‑month safety stock to buffer against supply interruptions.

Molekula, as a specialist supplier, offers pre‑validated PFAS‑free alternatives and can provide detailed CoA and SDS packages to support these strategies, though each case should be evaluated on its own merit.

Sources

• European Chemicals Agency. "PFAS Restriction under REACH".
• European Commission. "Press Release: EU adopts universal PFAS restriction" (2023). https://ec.europa.eu/commission/presscorner/detail/en/ip_23_1234
• Chemistry World. "PFAS REACH restriction: what it means for industry" (2024).
• European Commission. "Impact Assessment of the PFAS Restriction" (2025).
• ECHA. "Annual Compliance Report 2025".